Iain M. Cockburn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8154928/publications.pdf

Version: 2024-02-01

41 papers

8,458 citations

28 h-index 330143 37 g-index

60 all docs 60 docs citations

60 times ranked

4647 citing authors

#	Article	IF	CITATIONS
1	Measuring Competence? Exploring Firm Effects in Pharmaceutical Research. Strategic Management Journal, 1994, 15, 63-84.	7.3	2,049
2	Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery. RAND Journal of Economics, 1996, 27, 32.	2.3	898
3	Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery. Journal of Industrial Economics, 1998, 46, 157-182.	1.3	797
4	Gone but not forgotten: knowledge flows, labor mobility, and enduring social relationships. Journal of Economic Geography, 2006, 6, 571-591.	3.0	500
5	Untangling the origins of competitive advantage. Strategic Management Journal, 2000, 21, 1123-1145.	7.3	376
6	The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems. International Journal of Industrial Organization, 2003, 21, 1227-1253.	1.2	304
7	Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity. Information Systems Research, 2012, 23, 42-59.	3.7	301
8	Opportunity costs and entrepreneurial activity. Journal of Business Venturing, 1995, 10, 95-106.	6.3	256
9	The Changing Structure Of The Pharmaceutical Industry. Health Affairs, 2004, 23, 10-22.	5.2	195
10	Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. Journal of Health Economics, 2001, 20, 1033-1057.	2.7	172
11	Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. RAND Journal of Economics, 1997, 28, 426.	2.3	167
12	Mixed Poisson Regression Models with Covariate Dependent Rates. Biometrics, 1996, 52, 381.	1.4	151
13	<scp>Patents, Thickets and the Financing of Earlyâ€Stage Firms: Evidence from the Software Industry</scp> . Journal of Economics and Management Strategy, 2009, 18, 729-773.	0.8	121
14	Entry and Patenting in the Software Industry. Management Science, 2011, 57, 915-933.	4.1	118
15	Loss of Work Productivity due to Illness and Medical Treatment. Journal of Occupational and Environmental Medicine, 1999, 41, 948-953.	1.7	117
16	Patents and the survival of Internet-related IPOs. Research Policy, 2010, 39, 214-228.	6.4	113
17	Why are some regions more innovative than others? The role of small firms in the presence of large labs. Journal of Urban Economics, 2014, 81, 149-165.	4.4	113
18	Public-private interaction in pharmaceutical research. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12725-12730.	7.1	105

#	Article	IF	CITATIONS
19	Patents and the Global Diffusion of New Drugs. American Economic Review, 2016, 106, 136-164.	8.5	102
20	New Pills for Poor People? Empirical Evidence after GATT. World Development, 2001, 29, 265-289.	4.9	100
21	Not Invented Here? Innovation in company towns. Journal of Urban Economics, 2010, 67, 78-89.	4.4	90
22	Impact of Clinical Trial Results on National Trends in \hat{l}_{\pm} -Blocker Prescribing, 1996-2002. JAMA - Journal of the American Medical Association, 2004, 291, 54.	7.4	84
23	DO FIRMS CHANGE CAPABILITIES BY HIRING NEW PEOPLE? A STUDY OF THE ADOPTION OF SCIENCE-BASED DRUG DISCOVERY. Advances in Strategic Management, 0, , 133-159.	0.1	81
24	National trends in asthma visits and asthma pharmacotherapy, 1978-2002. Journal of Allergy and Clinical Immunology, 2003, 111, 729-735.	2.9	70
25	The Market For Follow-On Biologics: How Will It Evolve?. Health Affairs, 2006, 25, 1291-1301.	5.2	69
26	Patent thickets, licensing and innovative performance. Industrial and Corporate Change, 2010, 19, 899-925.	2.8	67
27	A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clinical Therapeutics, 2003, 25, 1503-1517.	2.5	61
28	The Impact of Incremental Innovation in Biopharmaceuticals. Pharmacoeconomics, 2006, 24, 69-86.	3.3	42
29	Analysis of Patent Data: A Mixed-Poisson-Regression-Model Approach. Journal of Business and Economic Statistics, 1998, 16, 27.	2.9	33
30	Deals not done: Sources of failure in the market for ideas. Strategic Management Journal, 2015, 36, 976-986.	7.3	33
31	Faster, smaller, cheaper: an hedonic price analysis of PDAs. Applied Economics, 2008, 40, 2839-2856.	2.2	32
32	The Hidden Cost Of Low Prices: Limited Access To New Drugs In India. Health Affairs, 2014, 33, 1567-1575.	5.2	31
33	Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases. Clinical Trials, 2010, 7, 719-734.	1.6	28
34	Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy. Capitalism and Society, 2010, 5, .	0.3	19
35	Hedonic Analysis of Arthritis Drugs. , 0, , 439-458.		15
36	Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms. Research Policy, 2013, 42, 529-541.	6.4	14

#	Article	IF	CITATIONS
37	Patent Thickets, Licensing and Innovative Performance. SSRN Electronic Journal, 0, , .	0.4	10
38	Diffusion of New Drugs in the Post-TRIPS Era. International Journal of the Economics of Business, 2011, 18, 203-224.	1.7	8
39	Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics, 1999, 21, 917-924.	2.5	4
40	O Brave New Industry, That Has Such Patents in It! Reflections on the Economic Consequences of Patenting DNA. Advances in Genetics, 2003, 50, 385-398.	1.8	4
41	National Bureau of Economic Research Patent Database: Audio of Presentation. SSRN Electronic Journal, 0, , .	0.4	0